Meeting
2011 ASCO Annual Meeting
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.
Authors
S. R. Alberts
Mayo Clinic, Rochester, MN
S. R. Alberts , S. N. Thibodeau , D. J. Sargent , M. R. Mahoney , F. Sinicrope , A. F. Shields , E. Chan , R. M. Goldberg , S. Gill , M. S. Kahlenberg , J. T. Quesenberry , T. C. Smyrk , A. Grothey , S. G. Nair
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00079274
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3607)
Abstract #
3607
Poster Bd #
18G
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.
First Author: Aziz Zaanan
Poster
2014 ASCO Annual Meeting
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.
First Author: Julien Taïeb
Poster
2017 ASCO Annual Meeting
Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.
First Author: Julien Taieb
Poster
2013 ASCO Annual Meeting
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance).
First Author: Frank A. Sinicrope